Why Names Got Weirder
17:32–18:21 · 49s
Sean and Scott outline FDA constraints—no implied promises and avoiding lookalike names—illustrated by why 'Flomax' might struggle today.
17:32–18:21 · 49s
Sean and Scott outline FDA constraints—no implied promises and avoiding lookalike names—illustrated by why 'Flomax' might struggle today.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.